The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.

ABSTRACT: Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body

SUBMITTER: Arriaga-Canon C 

PROVIDER: S-EPMC10138835 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature